CA
COGT icon

Crewe Advisors’s Cogent Biosciences COGT Stock Holding History

Crewe Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-386
Closed -$4.17K – 902
2023
Q1 		$4.17K Hold
386
– – ﹤0.01% 654
2022
Q4 		$4.46K Hold
386
– – ﹤0.01% 694
2022
Q3 		$6K Hold
386
– – ﹤0.01% 788
2022
Q2 		$3K Buy
+386
New +$2.63K ﹤0.01% 881

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Crewe Advisors's COGT Position: Q2 2023 in Review

Crewe Advisors sold out of Cogent Biosciences (COGT) in Q2 2023, closing a stake of 386 shares — an estimated $4.17K sold.

Crewe Advisors first reported a position in COGT in Q2 2022 and held it in 4 quarters. The position peaked at $6K in Q3 2022. 136 funds tracked by Wall St. Rank hold COGT as of Q2 2023.

  • Crewe Advisors reported no remaining Cogent Biosciences position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 386 Cogent Biosciences shares in Q2 2023, an estimated $4.17K.
  • Crewe Advisors first reported a position in Cogent Biosciences in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Cogent Biosciences position peaked at $6K in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.